Bluehole New Consumption Publishes a Feature Story on Recent Vaping Regulation Updates
4.11.2021 05:45:00 EET | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today published a feature story on recent vaping regulation updates in the UK, the US and Malaysia. As vaping accepted by more and more health regulators, the industry will witness a more concentrated and standardized market.
Here below is the full article in English:
On October 29, 2021, the U.K government agency, Medicines and Healthcare Products Regulatory Agency (MHRA) announced that NHS could soon prescribe e-cigarettes to help tobacco smokers quit, inviting e-cigarette manufacturers to submit products to undergo the same approval process as prescribed medicines. It could make England the first country to prescribe medicinally licensed e-cigarettes. Under such a circumstance, “A medically licensed e-cigarette would have to pass even more rigorous safety checks than those required for them to be sold commercially,” according to BBC.
On the same day, the Malaysian government announced to impose excise duty on nicotine vapor products. The managing director of British America Tobacco (BAT) Malaysia, Nedal Salem, said this indicates the Malaysian government is looking to legalize nicotine vapor products: “Regulation will not only allow vape users access to reduced-risk alternatives to smoking, but also ensure the products used are compliant to quality and safety standards.”
Meanwhile, in October, the U.S Food and Drug Administration (FDA) has granted marketing orders for Vuse Solo and accompanying tobacco flavored e-liquid pods, making it the first set of e-cigarette authorized for sale by the FDA.
From the UK to Malaysia and the U.S, E-cigarette is accepted by more and more health regulators around the world as an effective harm-reduction tool to improve public health.
As BAT Malaysia states, regulation could positively accelerate healthy development of the vaping industry for setting higher quality requirements and safety standards for products. Moreover, regulation measures, such as the marketing authorization and prescription evaluation, could be deemed the regulators’ acknowledgement of the products’ public health benefits.
Besides, Mitch Zeller, director of the FDA Center for Tobacco Products, said that “many of the tobacco product reviews are in final stages,” at a virtual conference hosted by the Food and Drug Law Institute on October 27. However, the agency so far has only authorized three products for their substantial evidence of harm reduction while issuing marketing denial orders for 200 thousand products.
Vuse is currently in a lead position to pass the Premarket Tobacco Product Applications (PMTA) process. It showcases that the FDA (and perhaps other regulators) is more likely to trust and approve products made by market leaders for assured public health benefits and reliability proved by sufficient scientific data.
The FDA’s rigorous requirements for products are also applied to manufacturers. SMOORE, the world’s largest vaping manufacturer, is the strategic supplier of VUSE. It features PMTA-related non-clinical evaluation capabilities, including physical testing, chemical testing and health risk assessment. Moreover, SMOORE’s CNAS tests have also expanded to 134.
As the regulatory framework outlines a higher entry barrier for the industry, the global vaping industry will witness a more standardized and concentrated market where industry leaders, such as BAT and SMOORE, will further strengthen their leading positions. Meanwhile, the whole industry and the supply chain will benefit from such a well-regulated and standardized market in turn.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/47350
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006380/en/
Contact information
Bluehole New Consumption Contact Info:
(+86)18612693874
CHEN ZHONG
SMOOR
Frankie Chen
(+86)13530848319
frankie.chen@smoorecig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 03:00:00 EEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY ® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 02:58:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform the future for people living with sickle cell disease and transfusion-dependent beta thalassemia. The remarkable consistency of results across age groups reinforces the potential of CASGEVY to deliver durable, transformative benefits to those who have historically had limited options,” said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. “We’re deeply grateful to the patients, families and investigators who pa
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 22:15:00 EEST | Press release
Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. Lenders and borrowers compete in real time, helping create more efficient markets and enabling financial products with better rates and terms for users. USDG supplied through Robinhood Earn is deposited into a Morpho Vault
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 21:33:00 EEST | Press release
SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leaders every year. “The Prism Awards are recognized across the optics and photonics industry
Around 500 Attend Sino-European ESG Conference in Germany1.7.2026 19:00:00 EEST | Press release
Around 500 government officials, business executives and academics from China and Europe gathered in the western German city of Mainz on Friday for the Third Sino-European Corporate ESG Best Practice Conference to discuss how deeper cooperation can support sustainable economic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701255421/en/ Group photo of selected attendees at the conference. Hosted by the Chinese Consulate General in Frankfurt and jointly organized with authorities from Germany and China, the conference brought together participants from China, Germany, France, Italy, the Netherlands, Denmark, Luxembourg and several other countries under the theme "From Vision to Practice: Empowering Sustainable Growth Through Collaboration." Francesco La Camera, Director-General of the International Renewable Energy Agency (IRENA), delivered a video address. Speaking at the opening ceremony, Huang Yiyang, Chinese Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
